CapsoVision, which makes a capsule endoscope system for diagnostic and screening applications, filed on Friday with the SEC to raise up to $30 million in an initial public offering.
CapsoVision develops advanced imaging and AI technologies that are deployed in its capsule endoscopy solutions to identify abnormalities of the gastrointestinal tract for diagnostic and screening purposes. The company developed its first capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease. CapsoVision is in the process of updating CapsoCam Plus to add its self-developed AI assisted reading technology and targeting related FDA 510(k) clearance of the updated capsule for late 2025, with commercialization shortly thereafter. Its AI assisted reading tools detect and highlight suspected abnormalities for a clinician.
The Saratoga, CA-based company was founded in 2005 and booked $12 million in revenue for the 12 months ended March 31, 2025. It plans to list on the Nasdaq under the symbol CV. CapsoVision filed confidentially on February 7, 2025. The Benchmark Company and Roth Capital are the joint bookrunners on the deal. No pricing terms were disclosed.
